Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 34Carcinoma, Non-Small-Cell Lung 15Breast Neoplasms 13Neoplasm Metastasis 9Triple Negative Breast Neoplasms 6Neoplasms 5Sarcoma 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Hodgkin Disease 3Carcinoma, Squamous Cell 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Multiple Myeloma 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Carcinoma 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Thrombocytosis 1Thoracic Neoplasms 1Squamous-Cell Non-Small-Cell Lung Cancer 1Spinal Cord Compression 1Solid Tumor 1

Interventions

Gemcitabine 25Cisplatin 19pembrolizumab 11avelumab 10Nivolumab 7Mitomycin 6Carboplatin 6apaziquone 5Paclitaxel 5Vinblastine 4Methotrexate 4Doxorubicin 4Docetaxel 4BCG Vaccine 4vofatamab 3durvalumab 3atezolizumab 3Sunitinib 3Standard of Care 3Sorafenib 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3Lapatinib 3Cystectomy 3B701 protein, Human herpesvirus 6 3valrubicin 2rucaparib 2enfortumab vedotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Urinary Bladder Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

SCRI Development Innovations, LLC

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡